Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management

Yeon Hee Park; Soo Chin Lee; Christian F Singer; Judith Balmaña; Rebecca Alexandra Dent; Veronique Kiak-Mien Tan; Nadia Ayu Mulansari; Mastura Md Yusof; Frances Victoria F Que; Yen-Shen Lu; Napa Parinyanitikul; Cam Phuong Pham; Nur Aishah Taib; Sun-Young Kong; Yoland Antill; Hee Jeong Kim

doi:10.3389/fonc.2026.1807980

Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management

Front Oncol. 2026 Mar 9:16:1807980. doi: 10.3389/fonc.2026.1807980. eCollection 2026.

Authors

Yeon Hee Park¹, Soo Chin Lee², Christian F Singer³, Judith Balmaña⁴, Rebecca Alexandra Dent⁵, Veronique Kiak-Mien Tan⁶, Nadia Ayu Mulansari⁷, Mastura Md Yusof⁸, Frances Victoria F Que⁹, Yen-Shen Lu¹⁰, Napa Parinyanitikul¹¹, Cam Phuong Pham^{12

13

14}, Nur Aishah Taib¹⁵, Sun-Young Kong¹⁶, Yoland Antill^{17

18}, Hee Jeong Kim¹⁹

Affiliations

¹ Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
² Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
³ Department of Obstetrics and Gynaecology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
⁴ Department of Medical Oncology, University Hospital Campus Vall Hebron, Barcelona, Spain.
⁵ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
⁶ Department of Breast Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
⁷ Haematology-Medical Oncology Division, Internal Medicine Department, Cipto Mangunkusumo National General Hospital/Universitas Indonesia, Jakarta, Indonesia.
⁸ Picaso Cancer Centre, Hospital Picaso, Petaling Jaya, Selangor, Malaysia.
⁹ Department of Internal Medicine and Oncology, St Luke's Medical Center, Quezon City and Global City, Metro Manila, Philippines.
¹⁰ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
¹¹ Medical Oncology Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
¹² The Nuclear Medicine and Oncology Center, Bachmai Hospital, Hanoi, Vietnam.
¹³ Nuclear Medicine Department, Hanoi Medical University, Hanoi, Vietnam.
¹⁴ Oncology and Nuclear Medicine Department, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
¹⁵ Department of Surgery, Faculty of Medicine, University Malaya, UM Cancer Research Institute, Kuala Lumpur, Malaysia.
¹⁶ Department of Laboratory Medicine and Genetic Counselling Clinic, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.
¹⁷ Familial Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia.
¹⁸ Faculty of Medicine and Health Sciences, Monash University, Melbourne, VIC, Australia.
¹⁹ Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Abstract

[This corrects the article DOI: 10.3389/fonc.2025.1507840.].

Keywords: BRCA germline pathogenic variants; HER2; PARP inhibitors; early breast cancer; triple-negative breast cancer.

Publication types

Published Erratum